Raily Aesthetic Medicine Proposes New Memorandum and Articles to Align With Regulatory Changes

Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has provided an announcement.

Raily Aesthetic Medicine International Holdings Limited plans to amend its existing second amended and restated memorandum and articles of association to align with updated Hong Kong Listing Rules and relevant Cayman Islands laws, including provisions related to an uncertificated securities market regime. The board proposes adopting a new third amended and restated memorandum and articles of association, which will replace the current version if shareholders approve the changes by special resolution at the 2026 annual general meeting, with further details to be sent in a forthcoming circular.

The proposed governance changes signal the company’s effort to modernize its constitutional documents and ensure compliance with evolving regulatory standards in Hong Kong and the Cayman Islands. This move may streamline the handling of the company’s listed securities, enhance regulatory alignment, and provide greater clarity and efficiency for shareholders and other market stakeholders once approved.

The most recent analyst rating on (HK:2135) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on Raily Aesthetic Medicine International Holdings Limited stock, see the HK:2135 Stock Forecast page.

More about Raily Aesthetic Medicine International Holdings Limited

Raily Aesthetic Medicine International Holdings Limited is a Hong Kong-listed company incorporated in the Cayman Islands, operating in the aesthetic medicine sector. The company focuses on providing medical aesthetic services, serving consumers seeking cosmetic and aesthetic treatments in Mainland China and potentially broader Asian markets.

Average Trading Volume: 443,728

Technical Sentiment Signal: Hold

Current Market Cap: HK$84.68M

For a thorough assessment of 2135 stock, go to TipRanks’ Stock Analysis page.